Karl Bjorkstrom
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 24, 2026
Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.
Journal: Journal of the National Cancer Institute
Published: March 11, 2026
Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field.
Journal: Journal of internal medicine
Published: February 14, 2026
Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma-Different Outcomes Between Patients With Lymph Node and In-transit Metastases.
Journal: Annals of surgery
Published: February 06, 2026
SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.
Journal: Acta oncologica (Stockholm, Sweden)
Published: December 17, 2025
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.
Journal: Journal of the National Cancer Institute
Published: July 24, 2025
Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 25, 2025
Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 02, 2021
Etiologies and outcomes of cirrhosis in a large contemporary cohort.
Journal: Scandinavian journal of gastroenterology
Published: April 19, 2021
A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis.
Journal: European journal of gastroenterology & hepatology
Published: August 16, 2020
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: January 20, 2019
Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: November 16, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026